[
    {
        "pregunta": "1. What are the accepted outcome measures specified by regulatory agencies for the approval of treatments for Psoriatic Arthritis?",
        "respuesta": "The accepted outcome measures specified by regulatory agencies for the approval of treatments for Psoriatic Arthritis (PsA) include the American College of Rheumatology 20% response criteria (ACR20) and the Psoriasis Area and Severity Index 75% response criteria (PASI75).",
        "contexto": [
            "(Figure 2 2 The panels chose the critical outcomes for all comparisons at the initial scoping; these included the American College of Rheumatology 20% response criteria (ACR20) (the primary outcome for most PsA clinical trials), the Health Assessment Questionnaire disability index (a measure of physical function), the PASI 75% response criteria (PASI75) (a measure of skin psoriasis improvement), and serious infections. Both the ACR20 and the PASI75 are accepted outcome mea sures specified by",
            "Both the ACR20 and the PASI75 are accepted outcome mea sures specified by regulatory agencies, including the US FDA, for the approval of treatments for PsA Moving from evidence to recommendations. GRADE methodology specifies that panels make recommendations based on the balance of benefits and harms, the quality of the evidence (i.e., confidence in effect estimates), and patients' values and preferences. Deciding on the balance between desirable and undesirable outcomes requires estimating the",
            "Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis,",
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis      90D16D20B18D6C2F67C5D476A40ED8A9 10.1002/art.40726  INTRODUCTION Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis, manifesting most commonly with peripheral arthritis, dactylitis, enthesitis, and spondylitis. Nail lesions, including pitting and onycholysis, occur in ~80-90% of patients with PsA. The incidence of PsA"
        ]
    },
    {
        "pregunta": "2. What is the GRADE methodology and how does it influence the recommendations for Psoriatic Arthritis treatment?",
        "respuesta": "The GRADE methodology, which stands for Grading of Recommendations, Assessment, Development and Evaluation, is a framework used for developing clinical guidelines. This methodology influences recommendations for Psoriatic Arthritis (PsA) treatment by considering the balance of relative benefits and harms of treatment options, the quality of evidence, and patients' values and preferences. The GRADE framework ensures a comprehensive, explicit, and transparent approach to guideline development, helping to make informed recommendations based on the best available evidence. For PsA, GRADE affects how outcomes such as the American College of Rheumatology 20% response criteria (ACR20) and the Psoriasis Area and Severity Index 75% response criteria (PASI75) are utilized in assessing the efficacy of treatments.",
        "contexto": [
            "in general [internal] medicine and rheumatologists). Methods For a detailed description of methods, see online supplementary file S1, on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ In brief, we used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework http://onlinelibrary.wiley.com/ http://onlinelibrary S1 http:// onlinelibrary.wiley.com/doi/10.1002/art.39333/abstract Results The results of the SLR are",
            "Both the ACR20 and the PASI75 are accepted outcome mea sures specified by regulatory agencies, including the US FDA, for the approval of treatments for PsA Moving from evidence to recommendations. GRADE methodology specifies that panels make recommendations based on the balance of benefits and harms, the quality of the evidence (i.e., confidence in effect estimates), and patients' values and preferences. Deciding on the balance between desirable and undesirable outcomes requires estimating the",
            "pharmacologic interventions, as well as the consensus judgment of clinical experts. The GRADE approach used provided a comprehensive, explicit, and transparent methodology for developing recommendations for OA management. The choice of any single or group of interventions may vary over the course of the disease or with patient and provider preferences, and is optimally arrived at through shared decision-making. The Voting Panel made strong recommendations for patients to participate in a",
            "in the setting of tofacitinib, will be addressed in a subsequent guideline update. The ACR has decided to use GRADE methodology in the development of guidelines for the management of rheumatic diseases. The GRADE methodology specifies that panels make recommendations based on a consideration of the balance of relative benefits and harms of the treatment options under consideration, the quality of the evidence (i.e., confidence in the evidence based on the lowest quality of the critical",
            "(as defined in Table 1 We used the GRADE method to develop these treatment recommendations in a way that was transparent, systematic, and explicit, and that was informed by the medical evidence as well as patient preferences. The major limitation of these guidelines is the very low quality of evidence for many recommendations, which necessitated reliance on the clinical expertise of the panel. For nonradiographic axial SpA, most recommendations were based on extrapolation of results from"
        ]
    },
    {
        "pregunta": "3. Why were conditional recommendations made for certain biologic treatments in Psoriatic Arthritis?",
        "respuesta": "Conditional recommendations for certain biologic treatments in Psoriatic Arthritis (PsA) were made due to the low-to very-low-quality evidence supporting these treatment options. A conditional recommendation implies that the desirable effects of following the recommendation probably outweigh the undesirable effects. This approach was chosen because the evidence quality is not strong enough to make definitive recommendations applicable to all patients. The conditional nature suggests that the course of action may benefit the majority of patients, but due to the low-quality evidence, some individuals might opt for different treatment paths based on their unique circumstances, preferences, and potential concerns such as adverse events, cost, or patient burden.",
        "contexto": [
            "may be considered instead of an IL-17i or IL- Recommendations for the treatment of patients with active psoriatic arthritis (PsA) despite treatment with oral small molecules (OSMs). All recommendations are conditional based on low-to very-low-quality evidence. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>",
            "In patients with active PsA despite treatment with an IL-12/23i biologic, switching to a TNFi biologic is recommended over adding MTX to the current regimen or switching to an IL-17i biologic A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional",
            "|Conditional recommendation based on low-quality evidence; may consider not following a treat-to-target strategy in patients in whom higher frequency and/or severity of adverse events, higher cost of therapy, or higher patient burden of medications with tighter control are a concern.| |\n|In patients with active PsA with psoriatic spondylitis/axial disease despite treatment with NSAIDs,‡| |\n|2. Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 46)|Very low|"
        ]
    },
    {
        "pregunta": "4. How does the high degree of heterogeneity in Psoriatic Arthritis presentation impact treatment decisions?",
        "respuesta": "The high degree of heterogeneity in Psoriatic Arthritis (PsA) presentation impacts treatment decisions for patients by creating challenges in capturing the full complexity and range of possible therapies in a single treatment algorithm. PsA is a heterogeneous and multifaceted inflammatory disease involving multiple domains such as peripheral arthritis, psoriasis, nail disease, enthesitis, dactylitis, and axial disease. These features sometimes respond differently to therapy, which complicates treatment selection. Additionally, the reporting of disease measures and differences in inclusion/exclusion criteria in PsA clinical trials make it difficult to compare therapies across trials. As a result, most treatment recommendations are based on low-quality evidence and are conditional, emphasizing the need for individualized treatment approaches that consider the specific clinical features and responses of each patient.",
        "contexto": [
            "do not account for the full complexity of PsA or the full range of possible therapies (e.g., glucocorticoids were not addressed). The high degree of heterogeneity in the presentation and course of PsA coupled with the involvement of multiple domains in a single patient cannot be captured in a single algorithm. In addition, reporting of disease measures and differences in inclusion/exclusion criteria in PsA clinical trials makes it difficult to compare therapies across trials. The impact of",
            "features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis, dactylitis, axial disease) sometimes respond differently to therapy. Despite an expansion in the number of new therapies for PsA, there remains limited comparative efficacy/effectiveness evidence to inform treatment decisions. Thus, most of our recommendations are based on low-quality evidence and are conditional. The conditional recommendations convey that, although the suggested course of action will be best for many",
            "Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis,",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "be performed to obtain high-quality data to fill in the evidentiary gaps (Supplementary Appendix 7, available on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/ Patient/caregiver input was instrumental in creating these recommendations. Several major themes emerged from their participation. Patients/caregivers stressed the need for individualizing treatments because what works for one does not work for all . To facilitate individualization, no rigid time frames were"
        ]
    },
    {
        "pregunta": "5. Why were vaccination recommendations with tofacitinib not included in the guideline?",
        "respuesta": "Vaccination recommendations with tofacitinib were not included in the guidelines for Psoriatic Arthritis because tofacitinib was not yet approved for PsA at the time when the PICO questions were drafted. Additionally, there was only a limited number of PICO questions that could be feasibly included for voting. It is mentioned that additional topics, including vaccination in the setting of tofacitinib, will be addressed in a subsequent update.",
        "contexto": [
            "makes it difficult to compare therapies across trials. The impact of alternative therapies on important outcomes such as joint damage still remains to be elucidated. Vaccination recommendations with tofacitinib were not included, as it was not yet approved for PsA when the PICO questions were drafted and only a limited number of PICO questions could be feasibly included for voting. Additional topics, including vaccination in the setting of tofacitinib, will be addressed in a subsequent",
            "<h1>Table 7. Recommendations for vaccination in patients with active psoriatic arthritis (PICOs 56–57)*</h1>",
            "management rather than addressing acute symptom management (i.e., through intraarticular injections and the use of systemic glucocorticoids). Tofacitinib and ixekizumab were submitted for review and potential approval by the US Food and Drug Administration (FDA) at the time of formulation of this guideline There are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. Thus, health care providers and patients should judge PsA and psoriasis severity on a",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>"
        ]
    },
    {
        "pregunta": "6. How does the GRADE methodology consider patient values and preferences in treatment recommendations?",
        "respuesta": "The GRADE methodology incorporates patient values and preferences into treatment recommendations by ensuring a transparent, systematic, and explicit approach that considers not only the balance of benefits and harms of treatments but also patient values and preferences. This comprehensive approach allows for shared decision-making between the patient and the clinician, particularly in situations where the evidence quality is low or very low, and the balance of benefits versus harms is sufficiently close. The GRADE framework helps to ensure that treatment recommendations are tailored to the specific circumstances, needs, and preferences of each patient, allowing for a more personalized approach to healthcare.",
        "contexto": [
            "evidence, including the balance of benefits and harms of treatments, the incorporation of patient values and preferences, and cost considerations to judge the tradeoff. This approach led to transparency in decision making by the Voting Panel for each clinical scenario and the formulation of these recommendations. Consistent with GRADE guidance, the Voting Panel usually offered a strong recommendation in the presence of moderate-or high-quality rating of the evidence, and a conditional",
            "http://onlin elibr ary.wiley.com/doi/10.1002/art.41142/ abstract Using GRADE, a recommendation can be either in favor of or against the proposed intervention and either strong or conditional The Voting Panel made conditional recommendations when the quality of the evidence proved low or very low and/ C I G O L O C A M R A H P APPROACHES or the balance of benefits versus harms and burdens was sufficiently close that shared decision-making between the patient and the clinician would be",
            "pharmacologic interventions, as well as the consensus judgment of clinical experts. The GRADE approach used provided a comprehensive, explicit, and transparent methodology for developing recommendations for OA management. The choice of any single or group of interventions may vary over the course of the disease or with patient and provider preferences, and is optimally arrived at through shared decision-making. The Voting Panel made strong recommendations for patients to participate in a",
            "(as defined in Table 1 We used the GRADE method to develop these treatment recommendations in a way that was transparent, systematic, and explicit, and that was informed by the medical evidence as well as patient preferences. The major limitation of these guidelines is the very low quality of evidence for many recommendations, which necessitated reliance on the clinical expertise of the panel. For nonradiographic axial SpA, most recommendations were based on extrapolation of results from",
            "to all recommendations, derived from input from the members of the Patient Panel were particularly salient in such situations. GRADE methodology allows the panels the possibility of not coming to a decision, and a summary of the discussion is noted in such cases. However, during the development of this guideline, the Voting Panel came to a conclusion in each case scenario, and such a situation did not arise. Consensus building. The Voting Panel voted on the direction and strength of the"
        ]
    },
    {
        "pregunta": "7. What are the limitations of the guideline in terms of comparative evidence and clinical scenarios covered?",
        "respuesta": "The limitations of the Psoriatic Arthritis (PsA) treatment guideline regarding comparative evidence and clinical scenarios are primarily due to the low or very low-quality evidence available. There were few or no head-to-head comparison studies identified during the literature review, which limits the ability to make strong, evidence-based recommendations. Additionally, the necessity of keeping the guideline task feasible meant not all possible clinical scenarios could be included. These limitations result in most recommendations being conditional, indicating that while the suggested course of action is appropriate for many patients, there may be cases where different treatment paths are necessary.",
        "contexto": [
            "comparative benefit/efficacy and harms evidence) and the inability to include all possible clinical scenarios due to the necessity of keeping the task feasible. Because the American Academy of Dermatology and the NPF are currently developing a guideline addressing therapy for psoriasis, our guideline did not address treatment of isolated psoriasis. Another limitation is that we searched only English-language literature. The major limitation of the work arises from the limitations in the",
            "subgroups. For most clinical scenarios (PICO questions) there were few or no head-to-head comparison studies identified in the literature review. Thus, the quality of evidence was most often low or very low, and only occasionally moderate (Supplementary Appendix 5; http://onlinelibrary.wiley.com/ doi/10.1002/art.40726/abstract The 2018 ACR/NPF guideline for the treatment of PsA will assist patients and their health care providers in making challenging disease management decisions. More",
            "features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis, dactylitis, axial disease) sometimes respond differently to therapy. Despite an expansion in the number of new therapies for PsA, there remains limited comparative efficacy/effectiveness evidence to inform treatment decisions. Thus, most of our recommendations are based on low-quality evidence and are conditional. The conditional recommendations convey that, although the suggested course of action will be best for many",
            "may be considered instead of an IL-17i or IL- Recommendations for the treatment of patients with active psoriatic arthritis (PsA) despite treatment with oral small molecules (OSMs). All recommendations are conditional based on low-to very-low-quality evidence. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>"
        ]
    },
    {
        "pregunta": "8. How does the guideline address the need for more comparative data to inform treatment selection in Psoriatic Arthritis?",
        "respuesta": "The guideline acknowledges the need for more comparative data to inform treatment selection in Psoriatic Arthritis (PsA). It highlights the limitation that, during the literature review, few or no head-to-head comparison studies were identified. This lack of comparative evidence results in the quality of evidence being low or very low, and only occasionally moderate. The guideline suggests that more comparative data are needed to better inform treatment selection and notes that several ongoing trials may provide additional information in the future. It anticipates future updates to the guideline when new evidence becomes available, which may help address the current limitations.",
        "contexto": [
            "comparative benefit/efficacy and harms evidence) and the inability to include all possible clinical scenarios due to the necessity of keeping the task feasible. Because the American Academy of Dermatology and the NPF are currently developing a guideline addressing therapy for psoriasis, our guideline did not address treatment of isolated psoriasis. Another limitation is that we searched only English-language literature. The major limitation of the work arises from the limitations in the",
            "subgroups. For most clinical scenarios (PICO questions) there were few or no head-to-head comparison studies identified in the literature review. Thus, the quality of evidence was most often low or very low, and only occasionally moderate (Supplementary Appendix 5; http://onlinelibrary.wiley.com/ doi/10.1002/art.40726/abstract The 2018 ACR/NPF guideline for the treatment of PsA will assist patients and their health care providers in making challenging disease management decisions. More",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "care providers in making challenging disease management decisions. More comparative data are needed to inform treatment selection. Several ongoing trials, including a trial to compare a TNFi biologic combination therapy with a TNFi biologic monotherapy and MTX monotherapy , will inform treatment decisions. We anticipate future updates to the guideline when new evidence is available."
        ]
    },
    {
        "pregunta": "9. What are the recommendations for the initial treatment of patients with active Psoriatic Arthritis who are treatment-naive?",
        "respuesta": "The provided information does not contain specific recommendations for the initial treatment of patients with active Psoriatic Arthritis who are treatment-naive. Therefore, I am unable to provide a reliable response based on the data available.",
        "contexto": [
            "<h1>Table 1. Recommendations for the initial treatment of patients with active psoriatic arthritis who are OSM- and other treatment–naive (PICOs 9–15)*</h1>",
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "<h1>Table 8. Recommendations for treatment of patients with active psoriatic arthritis with nonpharmacologic interventions (PICOs 1–8)*</h1>",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>"
        ]
    },
    {
        "pregunta": "10. How is Psoriatic Arthritis severity defined and how does it impact treatment decisions according to the guideline?",
        "respuesta": "The guideline does not provide a formal definition of Psoriatic Arthritis (PsA) severity but indicates that severity should be established on a case-by-case basis by the healthcare provider in collaboration with the patient. The development group mentions that severe PsA and psoriasis may be characterized by the presence of one or more items, and past definitions of severe psoriasis include a Psoriasis Area and Severity Index (PASI) score of 25 or higher. However, there are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. The severity assessment impacts treatment decisions by necessitating considerations of all active disease domains, comorbidities, and the patient's functional status to choose the optimal therapy for an individual at a given time.",
        "contexto": [
            "consideration all active disease domains, comorbidities, and the patient's functional status in choosing the optimal therapy for an individual at a given point in time. Examples of \"severe\" psoriatic arthritis (PsA) and psoriasis. The guideline development group defined severe PsA and psoriasis as the presence of 1 or more of the items listed. This is not a formal definition. There have been many definitions of severe psoriasis used over time-the items here are adapted from the 2007 National",
            "Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis,",
            "Network recommendations for spondyloarthritis (SpA). § Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 Table 5. (Cont'd) Active PsA with predominant enthesitis in treatment-naive patients and despite treatment with an OSM (Table 5 In",
            "2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis      90D16D20B18D6C2F67C5D476A40ED8A9 10.1002/art.40726  INTRODUCTION Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis, manifesting most commonly with peripheral arthritis, dactylitis, enthesitis, and spondylitis. Nail lesions, including pitting and onycholysis, occur in ~80-90% of patients with PsA. The incidence of PsA",
            "management rather than addressing acute symptom management (i.e., through intraarticular injections and the use of systemic glucocorticoids). Tofacitinib and ixekizumab were submitted for review and potential approval by the US Food and Drug Administration (FDA) at the time of formulation of this guideline There are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. Thus, health care providers and patients should judge PsA and psoriasis severity on a"
        ]
    }
]